245
Views
10
CrossRef citations to date
0
Altmetric
Clinical focus: Clinical Immunology & Infectious Diseases - Original research

Association of lipid profile with decompensation, liver dysfunction, and mortality in patients with liver cirrhosis

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 626-638 | Received 07 Dec 2020, Accepted 12 May 2021, Published online: 16 Jun 2021

References

  • Boemeke L, Bassani L, Marroni CA, et al. Lipid profile in cirrhotic patients and its relation to clinical outcome. Arq Bras Cir Dig. 2015;28(2):132–135.
  • Arain SQ, Talpur FN, Channa NA, et al. Serum lipid profile as a marker of liver impairment in hepatitis B Cirrhosis patients. Lipids Health Dis. 2017;16(1):51.
  • Kroon PA, Powell EE. Liver, lipoproteins and disease: i. Biochemistry of lipoprotein metabolism. J Gastroenterol Hepatol. 1992;7(2):214–224.
  • Jeon S, Carr R. Alcohol effects on hepatic lipid metabolism. J Lipid Res. 2020;61(4):470–479.
  • Palmer LB, Kuftinec G, Pearlman M, et al. Nutrition in Cirrhosis. Curr Gastroenterol Rep. 2019;21(8):38.
  • Bassendine MF, Sheridan DA, Felmlee DJ, et al. HCV and the hepatic lipid pathway as a potential treatment target. J Hepatol. 2011;55(6):1428–1440.
  • André P, Perlemuter G, Budkowska A, et al. Hepatitis C virus particles and lipoprotein metabolism. Semin Liver Dis. 2005;25(1):93–104.
  • Aizawa Y, Seki N, Nagano T, et al. Chronic hepatitis C virus infection and lipoprotein metabolism. World J Gastroenterol. 2015;21(36):10299–10313.
  • Halsted CH. Nutrition and alcoholic liver disease. Semin Liver Dis. 2004;24(3):289–304.
  • Ghadir MR, Riahin AA, Havaspour A, et al. The relationship between lipid profile and severity of liver damage in cirrhotic patients. Hepatitis Mon. 2010;10(4):285–288.
  • Chrostek L, Supronowicz L, Panasiuk A, et al. The effect of the severity of liver cirrhosis on the level of lipids and lipoproteins. Clin Exp Med. 2014;14(4):417–421.
  • Janicko M, Veseliny E, Lesko D, et al. Serum cholesterol is a significant and independent mortality predictor in liver cirrhosis patients. Ann Hepatol. 2013;12(4):581–587.
  • Peng Y, Qi X, Child-Pugh Versus GX. MELD Score for the Assessment of Prognosis in Liver Cirrhosis: a Systematic Review and Meta-Analysis of Observational Studies. Medicine (Baltimore). 2016;95(8):e2877.
  • Lippi G, Dipalo M, Musa R, et al. Evaluation of the analytical performances of the novel Beckman Coulter AU5800. Clin Biochem. 2012;45(6):502–504.
  • Guidelines for the diagnosis and treatment of liver cirrhosis. Chinese Journal of Hepatology, Chinese Medical Association. 2019;11:846–865.
  • Sarin SK, Kedarisetty CK, Abbas Z, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014. Hepatol Int. 2014;8(4):453–471.
  • Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259.
  • Bassani L, Fernandes SA, Raimundo FV, et al. LIPID PROFILE OF CIRRHOTIC PATIENTS AND ITS ASSOCIATION WITH PROGNOSTIC SCORES: a cross-sectional study. Arq Gastroenterol. 2015;52(3):210–215.
  • Tauseef A, Zafar M, Rashid B, et al. Correlation of Fasting Lipid Profile in Patients With Chronic Liver Disease: a Descriptive Cross-Sectional Study in Tertiary Care Hospital. Cureus. 2020;12(10):e11019.
  • Shah SS, Desai HG. Apolipoprotein deficiency and chronic liver disease. J Assoc Physicians India. 2001;49:274–278.
  • Jackson AA. Nutrition and Liver Health. Dig Dis. 2017;35(4):411–417.
  • Amodio P, Bemeur C, Butterworth R, et al. The nutritional management of hepatic encephalopathy in patients with cirrhosis: international Society for Hepatic Encephalopathy and Nitrogen Metabolism Consensus. Hepatology. 2013;58(1):325–336.
  • Hanai T, Shiraki M, Nishimura K, et al. Free fatty acid as a marker of energy malnutrition in liver cirrhosis. Hepatol Res. 2014;44(2):218–228.
  • Nishikawa H, Osaki Y. Liver Cirrhosis: evaluation, Nutritional Status, and Prognosis. Mediators Inflamm. 2015;2015:872152.
  • Huisman EJ, Trip EJ, Siersema PD, et al. Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol. 2011;23(11):982–989.
  • Tandon P, Raman M, Mourtzakis M, et al. A practical approach to nutritional screening and assessment in cirrhosis. Hepatology. 2017;65(3):1044–1057.
  • Acharya C, Bajaj JS, Microbiota G. Complications of Liver Disease. Gastroenterol Clin North Am. 2017;46(1):155–169.
  • Yu Y, Raka F. The Role of the Gut Microbiota in Lipid and Lipoprotein Metabolism. J Clin Med. 2019;8(12):12.
  • Hrabovský V, Mendlová A, Zadák Z, et al. Cholesterol metabolism in acute upper gastrointestinal bleeding, preliminary observations. Wien Klin Wochenschr. 2012;124(23–24):815–821.
  • Maharshi S, Sharma BC, Srivastava S. Malnutrition in cirrhosis increases morbidity and mortality. J Gastroenterol Hepatol. 2015;30(10):1507–1513.
  • Privitera G, Spadaro L, Marchisello S, et al. Abnormalities of Lipoprotein Levels in Liver Cirrhosis: clinical Relevance. Dig Dis Sci. 2018;63(1):16–26.
  • Simon TG, Butt AA. Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World J Gastroenterol. 2015;21(27):8293–8303.
  • He Y, Kothari V, Bornfeldt KE. High-Density Lipoprotein Function in Cardiovascular Disease and Diabetes Mellitus. Arterioscler Thromb Vasc Biol. 2018;38(2):e10–e6.
  • Tosheska Trajkovska K, Topuzovska S. High-density lipoprotein metabolism and reverse cholesterol transport: strategies for raising HDL cholesterol. Anatol J Cardiol. 2017;18(2):149–154.
  • Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96(12):1221–1232.
  • Habib A, Mihas AA, Abou-Assi SG, et al. High-density lipoprotein cholesterol as an indicator of liver function and prognosis in noncholestatic cirrhotics. Clin Gastroenterol Hepatol. 2005;3(3):286–291.
  • Trieb M, Rainer F, Stadlbauer V, et al. HDL-related biomarkers are robust predictors of survival in patients with chronic liver failure. J Hepatol. 2020;73(1):113–120.
  • Galbois A, Thabut D, Tazi KA, et al. Ex vivo effects of high-density lipoprotein exposure on the lipopolysaccharide-induced inflammatory response in patients with severe cirrhosis. Hepatology. 2009;49(1):175–184.
  • Guo L, Ai J, Zheng Z, et al. High density lipoprotein protects against polymicrobe-induced sepsis in mice. J Biol Chem. 2013;288(25):17947–17953.
  • Tsai MH, Peng YS, Chen YC, et al. Low serum concentration of apolipoprotein A-I is an indicator of poor prognosis in cirrhotic patients with severe sepsis. J Hepatol. 2009;50(5):906–915.
  • Van Der Stoep M, Korporaal SJ, Van Eck M. High-density lipoprotein as a modulator of platelet and coagulation responses. Cardiovasc Res. 2014;103(3):362–371.
  • Griffin JH, Kojima K, Banka CL, et al. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest. 1999;103(2):219–227.
  • Tripodi A, Anstee QM, Sogaard KK, et al. Hypercoagulability in cirrhosis: causes and consequences. J Thromb Haemost. 2011;9(9):1713–1723.
  • Gao B, Xiao J, Zhang M, et al. High-density lipoprotein cholesterol for the prediction of mortality in cirrhosis with portal vein thrombosis: a retrospective study. Lipids Health Dis. 2019;18(1):79.
  • Delgado-Coello B, Briones-Orta MA, Macías-Silva M, et al. Cholesterol: recapitulation of its active role during liver regeneration. Liver Int. 2011;31(9):1271–1284.
  • Manka P, Olliges V, Bechmann LP, et al. Low levels of blood lipids are associated with etiology and lethal outcome in acute liver failure. PLoS One. 2014;9(7):e102351.
  • Qi X, Arora A, Tang S, et al. Prognostic Assessment and Management of Liver Cirrhosis. Biomed Res Int. 2017;2017:5326898.
  • Wendon J, Bernal W, Willars C, et al. Critical care and cirrhosis: outcome and benefit. Curr Opin Crit Care. 2011;17(5):533–537.
  • Samuel D, Coilly A. Management of patients with liver diseases on the waiting list for transplantation: a major impact to the success of liver transplantation. BMC Med. 2018;16(1):113.
  • Miura K, Ohnishi H. Nonalcoholic fatty liver disease: from lipid profile to treatment. Clin J Gastroenterol. 2012;5(5):313–321.
  • Silva VM, Vinagre CG, Dallan LA, et al. Plasma lipids, lipoprotein metabolism and HDL lipid transfers are equally altered in metabolic syndrome and in type 2 diabetes. Lipids. 2014;49(7):677–684.
  • Peng K, Mo Z, Tian G. Serum Lipid Abnormalities and Nonalcoholic Fatty Liver Disease in Adult Males. Am J Med Sci. 2017;353(3):236–241.
  • Amor AJ, Perea V. Dyslipidemia in nonalcoholic fatty liver disease. Curr Opin Endocrinol Diabetes Obes. 2019;26(2):103–108.
  • Chou R, Dana T, Blazina I, et al. Statins for Prevention of Cardiovascular Disease in Adults: evidence Report and Systematic Review for the US Preventive Services Task Force. Jama. 2016;316(19):2008–2024.
  • Kaplan DE, Serper MA, Mehta R, et al. Effects of Hypercholesterolemia and Statin Exposure on Survival in a Large National Cohort of Patients With Cirrhosis. Gastroenterology. 2019;156(6):1693–706.e12.
  • Janicko M, Drazilova S, Pella D, et al. Pleiotropic effects of statins in the diseases of the liver. World J Gastroenterol. 2016;22(27):6201–6213.
  • Gu Y, Yang X, Liang H, et al. Comprehensive evaluation of effects and safety of statin on the progression of liver cirrhosis: a systematic review and meta-analysis. BMC Gastroenterol. 2019;19(1):231.
  • Tripathi DM, Vilaseca M, Lafoz E, et al. Simvastatin Prevents Progression of Acute on Chronic Liver Failure in Rats With Cirrhosis and Portal Hypertension. Gastroenterology. 2018;155(5):1564–1577.
  • Bays H, Cohen DE, Chalasani N, et al. An assessment by the Statin Liver Safety Task Force: 2014 update. J Clin Lipidol. 2014;8(3 Suppl):S47–57.
  • Kappus MR. Acute Hepatic Failure and Nutrition. Nutr Clin Pract. 2020;35(1):30–35.
  • Gonzáles Yovera JG, Concepción-Zavaleta MJ. Statins in liver cirrhosis in a developing country: benefits overweigh the risk? Expert Opin Drug Saf. 2020;19(12): 1651-2.
  • Bosch J, Gracia-Sancho J. Cirrhosis as new indication for statins. Gut. 2020;69(5):953–962.
  • Moctezuma-Velázquez C, Abraldes JG, Montano-Loza AJ. The Use of Statins in Patients With Chronic Liver Disease and Cirrhosis. Curr Treat Options Gastroenterol. 2018;16(2):226–240.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.